Home › Funds › Octagon Capital Advisors LP › GYRE

Octagon Capital Advisors LP position in GYRE

GYRE THERAPEUTICS INC · Health Care

Octagon Capital Advisors LP reported holding 954,416 shares of GYRE (GYRE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$7.0M, representing 0.93% of its reported portfolio and ranking #19 among its reported holdings. Octagon Capital Advisors LP has disclosed GYRE holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)954.42K sh
Reported value held$7.00M
Portfolio Weight0.93%
First reportedQ2 2026
Last changeHold
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Octagon Capital Advisors LP's GYRE position evolved

Octagon Capital Advisors LP first disclosed a stake in GYRE in Q2 2026 at 954,416 shares (US$6.3M). The position peaked in Q3 2026 at 954,416 shares, worth US$7.0M. Across 2 filings, Octagon Capital Advisors LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 954,416 shares valued at US$7.0M.

Quarter by quarter

QuarterSharesValueChange
Q2 2026 954.42K $6.29M New
Q3 2026 954.42K $7.00M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GYRE and 13F data

GYRE (GYRE THERAPEUTICS INC) is a Health Care company. 38 other funds we track also report a position in GYRE — the largest reported positions include HSG Holding Ltd (US$27.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GYRE

All GYRE fund holders →

FAQ

How long has Octagon Capital Advisors LP held GYRE?

Octagon Capital Advisors LP has disclosed GYRE holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Octagon Capital Advisors LP's current position in GYRE?

As of Q3 2026, Octagon Capital Advisors LP holds 954.42K shares of GYRE (GYRE THERAPEUTICS INC), valued at $7.00M, representing 0.93% of its reported portfolio and ranking #19.

Has Octagon Capital Advisors LP been buying or selling GYRE?

In the latest 13F filing (Q3 2026), Octagon Capital Advisors LP held unchanged its position in GYRE. The position peaked in Q3 2026 at 954.42K shares.

Which other funds hold GYRE?

Other major institutional holders of GYRE include HSG Holding Ltd, among 38 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.